Journal List > Korean J Hematol > v.44(2) > 1032813

Song, Roh, Ahn, Kim, Byoun, Choi, Hwang, Park, Choi, Kim, Kim, and Lee: Mutation of the N-ras Gene in a Patient Suffering from the Blast Phase of Chronic Myelogenous Leukemia

Abstract

The blast phase in chronic myelogenous leukemia (CML) is associated with mutation of several genes. It is well known that p53 gene mutation plays a key role in the myeloid or lymphoid blast phase of CML. But for the case of the N-ras gene, the association between N-ras mutations and the blast phase of CML is not yet known. We report here on a case of detecting N-ras point mutation without p53 mutation in a 64 year-old man who suffered from the lymphoblastic blast phase of CML.

References

1. Cline MJ, Jat PS, Foti A. Molecular mechanisms in the evolution of chronic myelocytic leukemia. Leuk Lymphoma. 1992; 7:283–7.
crossref
2. Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest. 1991; 87:2042–7.
crossref
3. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet. 2002; 3:179–98.
crossref
4. Malumbres M, Barbacid M. Ras oncogenes: the first 30 years. Nature. 2003; 3:7–13.
crossref
5. Shin DB, Kim YI, Kim JH, Kim SY, Yoon HJ, Cho KS. Point mutations of N-ras oncogene in acute myelogenous leukemia and myelodysplastic syndrome. Korean J Med. 1996; 50:94–105.
6. Barbacid M. Ras genes. Annu Rev Biochem. 1987; 56:779–827.
crossref
7. Gibbs JB, Marshall MS. The ras oncogene is an important regulatory element in lower eukaryotic organisms. Microbiol Rev. 1989; 53:171–85.
8. Neubauer A, Dodge RK, Geroge SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994; 83:1603–11.
crossref
9. Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndrome. Leukemia. 1994; 8:638–41.
10. LeMaistre A, Lee MS, Talpaz M, et al. Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood. 1989; 73:889–91.
crossref
11. Collins SJ, Howrd M, Andrews DF, Aqura E, Radich J. Rare ocurrence of N-ras point mutations in philadelphia chromosome positive chronic myelogenous leukemia. Blood. 1989; 73:1028–32.
12. Watzinger F, Gaiger A, Karlic H, Becher R, Pillwein K, Lion T. Absence of N-ras mutations in myeloid and lymphoid blast crisis of chronic myeloid leukemia. Cancer Res. 1994; 54:3934–8.

Fig. 1.
PCR-SSCP analysis of N-ras exon 1 in a patient with CML-blast phase. Band shift due to point mutation was detected on the arrowed sample. Controls included DNAs from a sample with known N-ras exon 1 mutation as a positive control (P), from normal lymphocytes as a normal control (W), and a negative control (no template DNA) (N).
kjh-44-100f1.tif
Fig. 2.
Dinucleotide sequencing of exon 1 of N-ras gene from DNA of a patient with CML-blast phase. Sequences are shown 5' (top) to 3' (bottom). A codon 13, GGT, was mutated to CGT, substituting an aminoacid arginine for glycine. Arrow indicates the base that has the point mutation.
kjh-44-100f2.tif
Fig. 3.
PCR-SSCP analysis of p53 gene of exon 5 (A), 6 (B), 7 (C), and 8 (D) in a patient with CML-blast phase. No band shift was observed in the patient (P).
kjh-44-100f3.tif
Table 1.
Lymphoma-leukemia marker study
Marker study result
Test/MoAb Result (%) CD Specificity
TdT 95   Nuclear TdT
Leu-9 2 CD7 T cell
T1 3 CD5 T cell
T11 7 CD2 T cell (E-rosette receptor)
I2 95   Ia-like Ag (HLA-D/DR)
B4 92 CD19 B cell
J5 56 CD10 CALLA
MY9 86 CD33 Myeloid
MY7 19 CD13 Myeloid
GPIIIa 0 CD61 Platelet GPIIIa
TOOLS
Similar articles